News articles about Endocyte (NASDAQ:ECYT) have trended somewhat negative recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Endocyte earned a news sentiment score of -0.04 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.6747822376521 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

Shares of Endocyte (NASDAQ ECYT) traded up 2.21% during mid-day trading on Friday, reaching $1.39. The company’s stock had a trading volume of 115,113 shares. Endocyte has a 52-week low of $1.17 and a 52-week high of $3.49. The company’s market capitalization is $59.18 million. The firm’s 50 day moving average is $1.38 and its 200-day moving average is $1.95.

Endocyte (NASDAQ:ECYT) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.03. The business had revenue of $0.01 million for the quarter. Endocyte had a negative net margin of 61,437.14% and a negative return on equity of 32.68%. During the same quarter last year, the firm earned ($0.25) earnings per share. Analysts forecast that Endocyte will post ($0.93) EPS for the current year.

A number of analysts recently commented on the company. Zacks Investment Research lowered Endocyte from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. ValuEngine lowered Endocyte from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 3rd. Wedbush reaffirmed an “outperform” rating on shares of Endocyte in a research note on Thursday, May 11th. Finally, Cowen and Company lowered Endocyte from an “outperform” rating to a “market perform” rating in a research note on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Endocyte currently has an average rating of “Hold” and an average target price of $3.58.

TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at

Endocyte Company Profile

Insider Buying and Selling by Quarter for Endocyte (NASDAQ:ECYT)

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.